GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » Cyclically Adjusted PS Ratio

Athersys (Athersys) Cyclically Adjusted PS Ratio : (As of May. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Athersys Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Athersys Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Athersys's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Cyclically Adjusted PS Ratio Chart

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 191.18 168.79 256.94 108.42 3.37

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.22 3.37 - 3.30 -

Competitive Comparison of Athersys's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Athersys's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athersys's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Athersys's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Athersys's Cyclically Adjusted PS Ratio falls into.



Athersys Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Athersys's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Athersys's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0/129.8595*129.8595
=0.000

Current CPI (Sep. 2023) = 129.8595.

Athersys Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.006 98.326 0.008
201403 0.001 99.695 0.001
201406 0.000 100.560 0.000
201409 0.001 100.428 0.001
201412 0.002 99.070 0.003
201503 0.001 99.621 0.001
201506 0.001 100.684 0.001
201509 0.000 100.392 0.000
201512 0.121 99.792 0.157
201603 0.180 100.470 0.233
201606 0.002 101.688 0.003
201609 0.002 101.861 0.003
201612 0.010 101.863 0.013
201703 0.012 102.862 0.015
201706 0.004 103.349 0.005
201709 0.002 104.136 0.002
201712 0.008 104.011 0.010
201803 0.006 105.290 0.007
201806 0.139 106.317 0.170
201809 0.016 106.507 0.020
201812 0.010 105.998 0.012
201903 0.010 107.251 0.012
201906 0.028 108.070 0.034
201909 -0.002 108.329 -0.002
201912 0.002 108.420 0.002
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.157 109.897 0.186
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.523 115.734 0.587
202112 0.076 117.630 0.084
202203 0.298 121.301 0.319
202206 0.223 125.017 0.232
202209 0.005 125.227 0.005
202212 0.002 125.222 0.002
202303 0.000 127.348 0.000
202306 0.002 128.729 0.002
202309 0.000 129.860 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Athersys  (OTCPK:ATHXQ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Athersys Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Athersys's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (Athersys) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Executives
Neema Mayhugh director 3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan director 100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo director, officer: Chief Executive Officer ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen officer: Chief Operating Officer 16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado officer: Interim, CFO 485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann officer: President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington director, officer: Chief Scientific Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell officer: Vice President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah director ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub director
Tadahisa Kagimoto director, 10 percent owner HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115

Athersys (Athersys) Headlines